<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02871271</url>
  </required_header>
  <id_info>
    <org_study_id>INQ/009416</org_study_id>
    <nct_id>NCT02871271</nct_id>
  </id_info>
  <brief_title>Tolerability and Benefit of IQP-AS-121 on Fatigue and Mental Alertness</brief_title>
  <official_title>Open-Label Pilot Study to Evaluate the Tolerability and Benefit of IQP-AS-121 on Fatigue and Mental Alertness in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>InQpharm Group</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>InQpharm Group</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the tolerability and benefit of IQP-AS-121 on
      reducing fatigue and tiredness and to improve mental alertness.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>November 2016</start_date>
  <primary_completion_date type="Anticipated">January 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in VAS-F parameter</measure>
    <time_frame>6 weeks</time_frame>
    <description>Compared between timepoints week 6 versus baseline
- To assess fatigue and energy with 18 items which possesses two subscales: fatigue (13 items) and energy (5 items).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Bond &amp; Lader VAS parameter</measure>
    <time_frame>6 weeks</time_frame>
    <description>Compared between timepoints week 6 versus baseline
- To assess alertness, contentedness and calmness</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Number Connection Test</measure>
    <time_frame>6 weeks</time_frame>
    <description>Compared between timepoints week 6 versus baseline
- To assess visuo-spatial orientation and cognitive processing speed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in FAIR-2</measure>
    <time_frame>6 weeks</time_frame>
    <description>Compared between timepoints week 6 versus baseline
- To measure attention as an ability to concentrate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in SF-12 parameter</measure>
    <time_frame>6 weeks</time_frame>
    <description>Compared between timepoints week 6 versus baseline
- To measure the overall health status of a subject</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in PSQ20 parameter</measure>
    <time_frame>6 weeks</time_frame>
    <description>Compared between timepoints week 6 versus baseline
- Contained 30 items as an instrument to assess subjectively experienced stress</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in POMS-35 parameters</measure>
    <time_frame>6 weeks</time_frame>
    <description>Compared between timepoints week 6 versus baseline
- The POMS-65 comprises 65 adjectives, separated into 6 subscales: 1) depression-dejection, 2) tension-anxiety, 3) anger-hostility, 4) confusion bewilderment, 5) fatigue-inertia and 6) vigour-activity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global evaluation of benefit</measure>
    <time_frame>6 weeks</time_frame>
    <description>Assessed by the subjects and investigator at the end of study
- To evaluate benefit of IP</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>6 weeks</time_frame>
    <description>Assessed throughout the study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global evaluation of tolerability</measure>
    <time_frame>6 weeks</time_frame>
    <description>Assessed by the subjects and investigator at the end of study</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Fatigue</condition>
  <arm_group>
    <arm_group_label>IQP-AS-121</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>To be taken once daily dosing of 1 tablet in the morning.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>IQP-AS-121</intervention_name>
    <arm_group_label>IQP-AS-121</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Caucasian males and females, 21-55 years of age

          2. Body mass index (BMI) 18.5-29.9 kg/m2

          3. Generally in good health without clinically significant findings at screening

          4. No chronic fatigue syndrome according to the Fukuda Centres for Disease Control and
             Prevention (CDC) criteria at screening

          5. Subjective feeling of chronic stress and tiredness for 3-12 last months prior to
             screening

          6. Screening Scale of Chronic Stress (SSCS) score &gt;18

          7. Fatigue Severity Scale score &gt;4

          8. ≤ 3 cups/portions of coffee and/or caffeine-containing food/beverages per day in the 3
             last months prior to screening and during the study

          9. Regular stable continuous level of daily activities

         10. Regular sleep-wake cycle

         11. Normal dietary habits according to investigator's judgement

         12. ≤ moderate level of physical exercise

         13. Readiness to comply with study procedures, in particular:

               -  Consumption of the IP during the treatment period

               -  Filling in all questionnaires

               -  Keep habitual diet and level of physical exercise

         14. No change in smoking habits during the study

         15. Women of child-bearing potential only:

               1. negative pregnancy testing (ß-HCG in urine at screening)

               2. commitment to use reliable contraception methods during the entire study
                  Participation is based upon written informed consent form (ICF) by the
                  participant following written and oral information by the investigator regarding
                  nature, purpose, consequences and possible risks of the clinical study.

        Exclusion Criteria:

          1. Known sensitivity to any components of the IP

          2. Any medical condition associated with tiredness (e.g. iron deficiency, hypotension
             etc.)

          3. History and/or presence of clinically significant disease, which per investigator's
             judgement could interfere with the results of the study or the safety of the subject:

               1. Psychiatric diseases, e.g. depression, schizophrenia

               2. Eating disorders such as anorexia

               3. Untreated or non-stabilized metabolic diseases, e.g. diabetes mellitus

               4. Untreated or non-stabilized thyroid disorder

               5. Untreated or non-stabilized hypertension (systolic blood pressure ≥140 mmHg
                  and/or diastolic blood pressure ≥90 mmHg)

               6. Significant gastrointestinal diseases

               7. Insomnia

               8. Known bleeding disorders such as haemophilia

               9. Any other known significant or serious condition / disease that renders subjects
                  ineligible (e.g. history of malignancy within the past 5 years prior to
                  screening, any clinically significant cardiovascular, renal, liver disease etc.)

          4. Use of medication which in the investigator's judgement could interfere with the
             results of the study (e.g. psychoactive medication, statins, proton pump inhibitors,
             blood-pressure medications, antihistamines, antibiotics, diuretics) within the last 4
             weeks prior to screening and during the study

          5. Consumption of vitamins, nutritional supplements, supplementary balanced diet, mineral
             products which in the investigator's judgement could interfere with the results of the
             study within last 4 weeks prior to screening and during the study

          6. Consumption of adaptogens (e.g. ginseng or Schisandra) or St. John's Wort within last
             4 weeks prior to screening and during the study

          7. Consumption of energy drinks during the study

          8. Start of use of contraception medication during the last 3 months prior to screening
             and during the study

          9. Use of anticoagulants such as warfarin

         10. Clinically significant deviation of laboratory parameters and/or deviations &gt; 2 x ULN
             (upper limit of normal) at screening

         11. Recent or current significant stressors (e.g. active grieving)

         12. Chronic pain

         13. Chronic sleep deficiency (&lt; 5 hours/night)

         14. Alcohol abuse (men: ≥21 units/week, women: ≥14 units/ week; 1 unit equals
             approximately 250 mL of beer, 100 mL of wine or 35 mL of spirits)

         15. Drug abuse

         16. Participation in another study during the last 30 days prior to screening

         17. Women of child-bearing potential: pregnant or breastfeeding

         18. Any situation expected during the study causing acute high level of stress

         19. Any other reason deemed suitable for exclusion as per investigator's judgment, e.g.
             insufficient compliance with study procedures
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ralf Uebelhack,, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>analyze &amp; realize GmbH</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ana Pekanovic, PhD</last_name>
    <phone>: +49 30/40 00 81 94</phone>
    <email>apekanovic@analyze-realize.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>analyze &amp; realize GmbH</name>
      <address>
        <city>Berlin</city>
        <zip>10369</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ralf Uebelhack, MD, PhD</last_name>
      <phone>+49 30/40 00 81 05</phone>
      <email>ruebelhack@analyze-realize.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 10, 2016</study_first_submitted>
  <study_first_submitted_qc>August 14, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 18, 2016</study_first_posted>
  <last_update_submitted>August 17, 2016</last_update_submitted>
  <last_update_submitted_qc>August 17, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 19, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fatigue</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

